Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals Liabilities

The The Liabilities of Recursion Pharmaceuticals (RXRX) as of Aug 7, 2026 is 343.27 M USD. In the previous year, The Liabilities was 413.82 M USD — a change of -17.05% (lower).

Liabilities

343.27 MUSD

YoY

-17.05%

Last updated:

In 2026, Recursion Pharmaceuticals's total liabilities amounted to 343.27 M USD, a -17.05% difference from the 413.82 M USD total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Recursion Pharmaceuticals's Liabilities

Recursion Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Recursion Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Recursion Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Recursion Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Recursion Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Recursion Pharmaceuticals stock

The Liabilities of Recursion Pharmaceuticals is 343.27 M USD in 2026.

The Liabilities of Recursion Pharmaceuticals changed from 413.82 M USD to 343.27 M USD, representing a -17.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Recursion Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Recursion Pharmaceuticals